3 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
The primary objective is to evaluate the added value of the IntelLeg Knee on the execution of activities of daily living for individuals with a transfemoral amputation when compared to the use of an auto-adaptive or mechanical (non-powered)…
The primary objective is to compare the IntelLeg Knee on the execution of a subset of daily activities for individuals with a transfemoral amputation to auto-adaptive or mechanical (non-powered) prosthetic knee via musculoskeletal simulation. The…